STRO-001
- Generic Name
- STRO-001
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 0D8BWL78LD
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase 1
Terminated
- Conditions
- B-cell LymphomaDiffuse Large B Cell LymphomaMantle Cell LymphomaNon Hodgkin LymphomaFollicular Lymphoma
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
- Target Recruit Count
- 9
- Registration Number
- NCT05611853
- Locations
- 🇨🇳
The First Affiliated School of Guangxi Medical University, Nanning, China
🇨🇳The first affiliated hospital, Zhejiang Unviersity school of medicine, Hangzhou, China
🇨🇳Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, China
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase 1
Completed
- Conditions
- Indolent LymphomaMultiple MyelomaDiffuse Large B Cell LymphomaNon Hodgkin LymphomaFollicular LymphomaB Cells--TumorsB-cell LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03424603
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath